Expert Insights on Managing Amivantamab Infusion Reactions, Dosing, and Medication

A pharmacy expert explores infusion-related reactions associated with amivantamab, providing guidance on managing and preventing these reactions, while also addressing the role of split-dosing, premedications, and steroids in the treatment paradigm.

EP: 1.Exploring EGFR Mutations and Prevalence in Non-Small Cell Lung Cancer

EP: 2.Examining Key Data from the FLAURA2 and MIRAPOSA Trials

EP: 3.Analyzing the MARIPOSA-2 Trial Data’s Impact on Clinical Practice

EP: 4.Exploring Key Insights from the PAPILLON Trial

EP: 5.Common Adverse Reactions to EGFR Therapy

Now Viewing

EP: 6.Expert Insights on Managing Amivantamab Infusion Reactions, Dosing, and Medication

EP: 7.Impact of Emerging Therapies on Outcomes for EGFR-Mutated NSCLC

Compared to the other EGFR-targeted therapies used in metastatic NSCLC, amivantamab is unique in carrying a risk for infusion-related reactions. What has been your experience with these infusion-related reactions, and what is the typical timing and severity of these reactions?
What preventative strategies do you recommend to help prevent infusion-related reactions with amivantamab?
Please discuss package insert recommendations including split-dosing and premedications, and if patients still experience infusion reactions despite these measures. Please discuss the role of preemptively including steroids as part of routine premedication (particularly when given as monotherapy and not already receiving steroids for pemetrexed purposes).
In your experience and in the context of these toxicities, how do patient-specific factors such as performance status and comorbidities influence the choice of EGFR-targeted therapies?
Please address considerations related to monotherapy vs. combination therapy (either with chemotherapy or other non-chemotherapy agents)